KAPVAY is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
The efficacy of KAPVAY is based on the results of two clinical trials in children and adolescents. Maintenance efficacy has not been systematically evaluated, and patients who are continued on longer-term treatment require periodic reassessment.

This extended-release formulation of clonidine hydrochloride is also approved for the
treatment of hypertension under the trade name JENLOGA.

Common and drug related adverse reactions (incidence at least 5% and twice the rate of placebo) reported with the use of KAPVAY include:

Somnolence, fatigue, upper respiratory tract infection (cough, rhinitis, sneezing), irritability, throat pain (sore throat), insomnia, nightmares, emotional disorder, constipation, nasal congestion, increased body temperature, dry mouth, and ear pain

• Sedating Drugs: Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs.
• Tricyclic Antidepressants: May reduce the hypotensive effect of clonidine.
• Drugs Known to Affect Sinus Node Function or AV Nodal Conduction: Caution is warranted in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers and beta-blockers) due to a potential for additive effects such as bradycardia and AV block.
• Use with other products containing clonidine: Do not use KAPVAY concomitantly with other products containing clonidine (e.g. Catapres).
• Antihypertensive drugs: Use caution when coadministered with KAPVAY.

• Hypotension/bradycardia: Use KAPVAY with caution in patients at risk for hypotension, bradycardia, and heart block. Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Advise patients to avoid becoming dehydrated or overheated.
• Somnolence/Sedation: Has been observed with KAPVAY. Consider the potential for additive sedative effects with CNS depressant drugs. Caution patients against operating heavy equipment or driving until they know how they respond to KAPVAY.
• Abrupt Discontinuation: Patients should be instructed not to discontinue KAPVAY therapy without consulting their physician due to the potential risk of withdrawal effects. KAPVAY should be discontinued slowly in decrements of no more than 0.1 mg every 3 to 7 days.